Published in final edited form as:

Expert Opin Drug Deliv. 2008 February ; 5(2): 149–153.

Applications of Glycosyltransferases in the Site-specific Conjugation of Biomolecules and Development of a Targeted Drug Delivery System and Contrast Agents for MRI

Boopathy Ramakrishnan^{1,2}, Elizabeth Boeggeman^{1,2}, and Pradman K. Qasba^{1,*}

¹ Structural Glycobiology Section, Center for Cancer Research, NCI-Frederick, Frederick, MD 21702

² Basic Research Program, SAIC-Frederick, Inc., Center for Cancer Research Nanobiology Program, Center for Cancer Research, NCI-Frederick, Frederick, MD 21702

Abstract

Background—The delivery of drugs to the proposed site of action is a challenging task. Tissue and cell-specific guiding molecules are being employed to carry a cargo of therapeutic molecule(s). The cargo molecules need to be conjugated in a site-specific manner to the therapeutic molecule(s) in a way that the bio-efficacy of these molecules are not compromised.

Methods—Using wild-type and mutant glycosyltransferases, the sugar moiety with a unique chemical handle is incorporated at a specific site into the cargo or therapeutic molecules, making it possible to conjugate these molecules via the chemical handle present on the modified glycan.

Results/conclusions—The modified glycan residues introduced at specific sites on the cargo molecule make it possible to conjugate fluorophores for ELISA-based assays, radionuclides for imaging and immunotherapy applications, lipids for the assembly of immunoliposomes, cytotoxic drugs, cytokines, or toxins for antibody-based cancer therapy and the development of a targeted drug-delivery system.

Keywords

Bioconjugation via glycan residues; MRI agents; cytotoxic agents; lipids; glycotargeting; drug delivery systems

Introduction

Targeting bioactive molecules to the site where they need to act has been quite challenging (1). They need guiding molecules that have to cross the endothelium, which is dependent on several factors, including the molecules' molecular weight and size. Small molecules are taken up by a cell, by a process that generally involves a specific transport mechanism, or by a passive diffusion process. In contrast, uptake of macromolecules by a cell involves receptor-mediated endocytosis or pinocytosis (2–4). These processes involve the interactions between the ligand and the receptors (5,6). Monoclonal or single-chain antibodies against ligands or receptors (7–9), tumor-homing (10) or cell-penetrating peptides (11) are being developed which act as tissue and cell-specific guiding molecules that have potential to carry bioactive molecules. The guiding molecules need to be conjugated with the bioactive agents in a site-specific manner.

*Corresponding author, Structural Glycobiology Section, CCRNP, CCR, NCI-Frederick, Building 469, Room 221, Frederick, Maryland 21702; e-mail: qasba@helix.nih.gov. Phone: (301) 846-1934; Fax: (301) 846-7149.

Methods of Bioconjugation

Various methods are being used with mixed success in conjugating peptides or antibodies with the cargo molecule (12,13). Often, the primary amine groups present on the surface of the protein molecule are used for conjugation; however, since every lysine residue present on the protein molecule would be reactive, this method results in undesirable heterogeneous conjugation and even loss of antibody activity. Recently, methods have been introduced for the site-specific coupling of biomolecules that include site-directed introduction and chemoselective ligation of cysteine residues to convert nonglycoproteins to glycoproteins (14), and site-directed introduction of azido/alkynyl-tagged methionine analogues into proteins (15). In the former method, either engineered or naturally present Cys residue, which is highly reactive in basic pH, requires special handling of the protein to prevent its free Cys residue from undergoing undesired oxidation. In the latter method, all the methionine residues present in the protein are modified. Carrica et al. have described a method for introducing genetically encoded aldehydes at either terminal end of proteins, which then can be used for conjugation (16). The sugar moieties present on the glycoproteins, such as IgG, upon periodate oxidation, provide aldehyde groups which have been used for coupling (17). However, the heterogeneous nature of the glycan moiety on the recombinant glycoprotein causes poor coupling. Various investigators are developing chemoenzymatic methods for site-specific conjugation of biomolecules (18,19).

Bioconjugation using mutant and wild-type glycosyltransferases

Oligosaccharides are attached at unique sites in proteins and glycolipids. They bring about specific geometries of interactions between the two glycoconjugates, resulting in the correct and efficient molecular interplay between various molecular structures (20).

Glycosyltransferases assemble the oligosaccharide structures on glycoconjugates. Recently, the structural information of several of these glycosyltransferases has become available (21), making it possible to engineer these enzymes so that they can transfer a non-preferred sugar residue (22) or sugar residue with a chemically reactive unique functional group (23). The presence of a modified sugar moiety with a chemical handle on a glycoconjugate makes it possible to link bioactive molecules via a modified glycan chain.

Based on the structural information, we have developed β 1, 4-galactosyltransferase mutant enzyme, Tyr298Leu-Gal-T1 (Y298L-Gal-T1) that transfers 2-acetonyl-2-deoxy-galactose (2-keto-Gal) or 2-*N*-acetyl-azide (GalNAz) from their UDP derivatives to *N*-acetylglucosamine residue, (GlcNAc), which is present at the non-reducing end of the glycans of glycoproteins (24). After the transfer of the modified sugar residue, the chemical handle is used for selective conjugation with various molecules (23). Using this method, we have shown that even the *N*-glycan moiety of the IgG molecule can be used as the substrate for the transfer of 2-keto-Gal sugar by the mutant Y298L-Gal-T1 (24). However, this method requires the presence of a free GlcNAc moiety on the non-reducing end of the glycan chain of the glycoprotein and cannot be used for non-glycoproteins, such as single-chain antibodies or bacterial toxins expressed in *E. coli*.

To conjugate nonglycoproteins via glycan residues, we have taken advantage of the polypeptide- α -*N*-acetylglucosaminyltransferase enzyme (ppGalNAc-T), which transfers *N*-acetylglucosamine sugar (GalNAc) from UDP-GalNAc to the Thr/Ser residues on an acceptor polypeptide that is at least 11 amino acids long (25). Using glutathione-S-transferase (GST) protein as a model system, we have engineered the fusion peptide sequence at its C-terminus, with a single Thr residue, which is the acceptor substrate for ppGalNAc-T2. The ppGalNAc-T2 not only transfers GalNAc, but also GalNAz or 2-keto-Gal from its UDP-derivative to the single Thr residue present in the fusion peptide tag of the GST.

Furthermore, we have expressed the soluble form of ppGalNAc-T2 in *E. coli* as inclusion bodies and developed an *in vitro* folding method to make large quantities of active ppGalNAc-T2 (25). Therefore, using ppGalNAc-T it is possible to glycosylate non-glycoproteins such as single-chain antibodies (scFv), bacterial toxins, etc., with a modified sugar carrying a unique chemical handle that can be used for conjugation.

General Utility of the Technique of Linking via Glycan Residue

The structural information available for glycosyltransferases has made it possible to design novel glycosyltransferases with broader and requisite donor specificities. Several mutant glycosyltransferases have been generated that can transfer a sugar residue with a chemically reactive functional group, e.g., 2-keto-galactose or GalNAz from their UDP-derivatives to N-acetylglucosamine residue of a glycoconjugates, such as to the oligosaccharide chain of IgG (24). Based on this technique, it was proposed that two glycoproteins with modified sugars having unique chemical handles may be conjugated with cross-linkers with orthogonal chemical reactive groups, thus enabling the design of novel immunotoxins and MRI contrast agents (Figure 1 [a]) (26). Nonglycoproteins can be glycosylated by engineering a C-terminal peptide tag that can be glycosylated with a modified sugar and coupled to a biomolecule that carries an orthogonal reactive group, making the method very useful in many nanobiological applications (25). Single-chain antibodies, instead of their full-length IgG counterparts, are increasingly used for immunotherapy (27), and they are easily expressed in large amounts in *E. coli* as soluble proteins. A fusion peptide attached at the C-terminal end of the scFv molecule can be glycosylated with a modified sugar at a unique site in the fusion peptide with ppGalNAc-T2 (25), and then conjugated with a biomolecule having an orthogonal reactive group, such as aminoxy or alkynes. This method of linking is more specific by simply glycosylating a fusion peptide attached at the C-terminal end of scFv, or homing peptides or cell-penetrating peptides, similar to the GST-tag protein. The glycan moiety with the modified sugar may then be conjugated with a lipid molecule having a corresponding reactive group, such as aminoxy or alkynes. Thus, the cargo molecules with lipid attached at their C-terminal end through their modified sugar moiety mimic the glycosyl-phosphatidylinositol (GPI) anchor of proteins, and they can be used for the formulation of the immunoliposomes (28). Such C-terminal modification in most scFv proteins seems to be feasible since their C-terminal end is away from their antigen-binding site (Fab) (Figure 1 [b]). Furthermore, repeats of fusion peptide sequence can be engineered at the C-terminal end of the cargo molecule, generating multiple glycosylation sites for conjugation (Figure 1 [c]). The linking techniques described (24,25), demonstrate that the sugar moieties with chemical handles incorporated at specific sites into mAb or scFv molecules by chemoenzymatic methods using glycosyltransferases can be used for linking various biomolecules at specific sites.

Expert Opinion Section

Delivering drugs or contrast agents to a specific target site for medical imaging is highly desirable for the diagnosis and treatment of many diseases, including cancer. For this purpose, target-specific monoclonal antibodies, single-chain antibodies, affibodies, and tumor-homing, cell-penetrating peptides have emerged as important guiding molecules that can carry a cargo of therapeutic molecule(s) to the desired site. Deploying these carrier molecules for a site-specific delivery of therapeutics molecules requires site-specific conjugation of these molecules with the cargo molecule(s). Utilizing wild-type or mutant glycosyltransferases to transfer a modified sugar residue with a chemical handle to a specific sugar moiety on a glycoconjugate or to a specific amino acid residue on a polypeptide chain, respectively, allows one to exploit these chemical handles for the bioconjugation of biomolecules. The monoclonal antibodies whose N-linked glycan moieties have been modified with the mutant β -1,4-galactosyltransferase to have 2-azido- or 2-keto-galactose can be conjugated with a

biomolecule having an corresponding orthogonal reactive group, such as alkynes or aminoxy, respectively. Similarly, a fusion peptide attached at the C-terminal end of a single chain antibody, affibody or a tumor-homing, cell-penetrating peptide, can be glycosylated at a unique site in the fusion peptide with a modified sugar; the glycosylated fusion peptide can then be conjugated with a biomolecule carrying an orthogonal reactive group. In addition, a cargo molecule having multiple conjugation sites at its C-terminal can be used to conjugate many scFv or affibodies, introducing multimeric antibody interactions to the target site. In the currently prevailing methods, generally a bi-functional cross-linker is used to cross-link two proteins at random sites to a protein residue distributed at several places on the protein surface. This method of cross-linking often blocks the functional sites on the protein and thus reduces the bioefficacy of the protein. The method of linking via glycan residues introduced at a specific site in the guiding molecules, such as mAb, scFv molecules, homing peptides or cell-penetrating peptides, makes it possible to conjugate cytokines; cytotoxic drugs; toxins for antibody-based cancer therapy (28); lipids for the assembly of immunoliposomes for the developing a targeted drug-delivery system (29); fluorophores for ELISA-based assays, radionuclides for imaging and immunotherapy applications.

Acknowledgements

This project has been funded in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract No. N01-CO-12400. The content of this publication does not necessarily reflect the view or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was supported [in part] by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

References

1. Jain RK. The next frontier of molecular medicine: Delivery of therapeutics. *Nat Med* 1998;4:655–7. [PubMed: 9623964]
2. Mukherjee S, Ghosh RN, Maxfield FR. Endocytosis. *Physiol Rev* 1997;77:759–803. [PubMed: 9234965]
3. Gao H, Shi W, Freund LB. Mechanics of receptor-mediated endocytosis. *Proc Natl Acad Sci USA* 2005;102:9469–74. [PubMed: 15972807]
4. Bao G, Bao XR. Shedding light on the dynamics of endocytosis and viral budding. *Proc Natl Acad Sci U S A* 2005;102:9997–9998. [PubMed: 16009932]
5. Vyas SP, Singh A, Sihorkar V. Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. *Crit Rev Ther Drug Carrier Syst* 2001;18:1–76. [PubMed: 11326743]
6. Russell-Jones GJ. The potential use of receptor-mediated endocytosis for oral drug delivery. *Adv Drug Deliv Rev* 2001;46:59–73. [PubMed: 11259833]
7. Hale G. Therapeutic antibodies – Delivering the promise? *Advanced Drug Delivery Reviews* 2006;58:633–9. [PubMed: 16822575]
8. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. *Nature Reviews Drug Discovery* 2006;5:147–59.
9. Hollinger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. *Nat Biotechnol* 2005;23:1126–36. [PubMed: 16151406]
10. Laakkonen P, Porkka K, Jason A, Hoffman, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. *Nature Medicine* 2002;8:751–5.
11. Jarver P, Langel U. Cell-penetrating peptides – A brief introduction. *Biochimica et Biophysica Acta* 2006;1758:260–3. [PubMed: 16574060]
12. Garnett MC. Targeted drug conjugates: principles and progress. *Adv Drug Deliv Rev* 2001;53:171–216. [PubMed: 11731026]
13. Wu AW, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. *Nature Biotechnology* 2005;23:1137–46.
14. Davis BG, Lloyd RC, Jones JB. Controlled site-selective glycosylation of proteins by a combined site-directed mutagenesis and chemical modification approach. *J Org Chem* 1998;63:9614–15.

15. Kiick KL, Saxon E, Tirrell DA, Bertozzi CR. Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation. *Proc Natl Acad Sci U S A* 2002;99:19–24. [PubMed: 11752401]
16. Carrico IS, Carlson BL, Bertozzi CR. Introducing genetically encoded aldehydes into proteins. *Nat Chem Biol* 2007;3:321–2. [PubMed: 17450134]
17. O'Shanessy DJ, Quarles RH. Labeling of the oligosaccharide moieties immunogloblins. *J Immunol Methods* 1987;99:153–61. [PubMed: 3035026]
18. Sato H, Hayashi E, Yamada N, Yatagai M, Takahara Y. Further studies on the site-specific protein modification by microbial transglutaminase. *Bioconjug Chem* 2001;12:701–10. [PubMed: 11562188]
19. Zhou Z, Cironi P, Lin AJ, Xu Y, Hrvatin S, Golan DE, Silver PA, Walsh CT, Yin J. Genetically encoded short peptide tags for orthogonal protein labeling by Sfp and Acps phosphopantetheinyl transferases. *ACS Chemical Biology* 2007;2:337–46. [PubMed: 17465518]
20. Qasba PK. Involvement of sugars in protein-protein interactions. *Carbohydrate Polymers* 2000;41:293–309.
21. Qasba PK, Ramakrishnan B, Boeggeman E. Substrate-induced conformational changes in glycosyltransferases. *Trends Biochem Sci* 2005;30:53–62. [PubMed: 15653326]
22. Ramakrishnan B, Qasba PK. Structure-based design of beta-1,4-Galactosyl-transferase-I (beta 4Gal-T1) with equally efficient N-Acetylgalactosaminyltransferase activity. *J Biol Chem* 2002;277:20833–40. [PubMed: 11916963]
23. Khidekel N, Arndt S, Lamarre-Vincent N, Lippert A, Poulin-Kerstien KG, Ramakrishnan B, Qasba PK, Hsieh-Wilson LC. A Chemoenzymatic approach toward the rapid and sensitive detection of *O*-GlcNAc posttranslational modifications. *J Am Chem Soc* 2003;125:16162–3. [PubMed: 14692737]
24. Boeggeman E, Ramakrishnan B, Kilgore C, Khidekel N, Hsieh-Wilson LC, Simpson JT, Qasba PK. Direct Identification of Nonreducing GlcNAc Residues on N-Glycans of Glycoproteins Using a Novel Chemoenzymatic Method. *Bioconjug Chem* 2007;18:806–14. [PubMed: 17370997]
25. Ramakrishnan B, Boeggeman E, Qasba PK. Novel Method for *in Vitro* O-glycosylation of Proteins: Application for Bioconjugation. *Bioconjug Chem* 2007;18:1912–18. [PubMed: 17953440]
26. Qasba PK, Ramakrishnan B, Boeggeman E. Mutant glycosyltransferases assist in the development of a targeted drug delivery system and contrast agents for MRI. *Am Ass Pharm Soc J* 2006;8:190–5.
27. Hollinger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. *Nat Biotechnol* 2005;23:1126–36. [PubMed: 16151406]
28. Park JW, Banz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. *Semin Oncol* 2004;31:196–205. [PubMed: 15717745]
29. Carter P. Improving the efficacy of antibody-based cancer therapies. *Nature Reviews Cancer* 2001;1:118–29.

Figure 1.

Schematic diagram showing immunoconjugate molecules conjugated through modified glycans. (a) Using the Y289L-Gal-T1 mutant, the modified sugar 2-keto-Gal can be transferred to the free GlcNAc residue present in the non-reducing end of the N-glycan naturally present on the Fc domain of IgG. The modified Gal residue can be conjugated to the therapeutic or toxin molecule having a modified sugar present at its C-terminal end through its glycan moieties. (b) Using ppGalNAc-T, the scFv molecule with a fusion peptide at its C-terminal end can be glycosylated with a modified sugar that can be conjugated with a lipid molecule with the corresponding reactive group. Thus, these scFv conjugates can be used for the formulation of the immuno-liposomes for the delivery of therapeutic molecules. (c) Cargo molecules, such as the toxins, with repeats of fusion peptide sequence at their C-terminal ends, have multiple glycosylation sites can be conjugated with many scFv molecules, thus enabling a multivalent recognition of the target site.